Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 3Thyroid Neoplasms 2Thyroid Carcinoma, Anaplastic 2Zollinger-Ellison Syndrome 1Thyroid Cancer, Papillary 1Somatostatinoma 1Pheochromocytoma 1Paraganglioma, Extra-Adrenal 1Paraganglioma 1Multiple Endocrine Neoplasia Type 1 1Insulinoma 1Glucagonoma 1Carcinoma, Medullary 1Adenocarcinoma, Follicular 1

Interventions

3-Iodobenzylguanidine 14Temozolomide 6lutetium Lu 177 dotatate 5gallium Ga 68 dotatate 4anlotinib 4Specimen Handling 4Everolimus 4Radiotherapy 3Phenoxybenzamine 3Magnetic Resonance Spectroscopy 3Doxorubicin 36-fluorodopamine 33-fluorobenzylguanidine 3pegfilgrastim 2olaparib 2fluorodopa F 18 2cabozantinib 2belzutifan 2Nivolumab 2Ifosfamide 2Granulocyte Colony-Stimulating Factor 2Fluorodeoxyglucose F18 2Filgrastim 2Doxazosin 2Dexmedetomidine 2Capecitabine 2Biopsy 2Axitinib 2Adrenalectomy 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pheochromocytoma × pazopanib × Endocrine × Clear all
NCT01340794 2017-09-21

Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma

National Cancer Institute (NCI)

Phase 2 Terminated
7 enrolled 8 charts
CNSEndocrine

Paraganglioma, Paraganglioma, Extra-Adrenal, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡